UNSPSC 51401515: Clobazam

This classification denotes an anxiolytic with the molecular formula C16H13ClN2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2MRO291B4U, chemically known as 7-chloro-1-methyl-5-phenyl-1h-1,5-benzodiazepine-2,4(3h,5h)-dione but generally known as clobazam, which bears US NIH Compound Identifier 2789. European Medicines Agency schedules Clobazam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06673MIG.

UNSPSC 51401515 Clobazam is a Commodity code that nominally describes a specific anticonvulsant pharmaceutical, but recent state and local solicitations tagged under this code show no alignment with the pharmaceutical scope. The single recent opportunity on record—Seminole County, Florida's IFB60459723LAS, posted June 30, 2026 with a response deadline of July 26, 2023—solicits 1,900 units of naloxone and 800 safe drug deactivation systems annually, products entirely outside the clobazam classification. This mismatch indicates either a tagging error in the procurement database or a divergence between the code's nominal pharmaceutical definition and how state and local bodies are using the code in practice. The naloxone and drug-deactivation procurement reflects public-health and emergency-response priorities rather than anticonvulsant therapy, and vendors responding would supply community health goods through quarterly deliveries to a single specified location in Sanford, Florida, with all shipping and delivery costs included in bid pricing.

Seminole County, a Florida county government, is the only issuing body appearing in recent activity under this code. The geographic footprint is limited to central Florida based on the single posted opportunity. Bidders in the Seminole County solicitation must comply with drug-free workplace certification, E-Verify requirements, and various insurance coverage mandates including workers' compensation, commercial general liability, and professional liability. The contract structure includes a two-year initial term with a one-year renewal option and a three-month probationary termination window. Because only one recent opportunity ties to this code and the scope bears no relationship to clobazam pharmaceuticals, this code shows little relevant recent activity for firms pursuing anticonvulsant supply or pharmaceutical distribution contracts with state and local bodies.